子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 一种测定Kappa游离轻链浓度的试剂盒及方法 | CN201310396461.0 | 2013-09-03 | CN103728455A | 2014-04-16 | 王金凤; 蒋欣 |
| 本发明公开了一种测定Kappa游离轻链浓度的试剂盒及方法。该试剂盒包括反应缓冲液和Kappa游离轻链抗体溶液，所述的反应缓冲液中氯化钠的浓度为1250～2400mmol/L。本发明的试剂盒解决了Kappa游离轻链比浊测定中的临床标本线性差的问题，为临床医生提供可靠的Kappa游离轻链测定结果作为诊断参考，以便充分发挥胶乳增强免疫比浊方法速度快，通量高的优势，缩短检测时间，利于临床应用和病人诊断。 | ||||||
| 2 | 治疗缺铁性贫血的方法 | CN201380050782.3 | 2013-07-26 | CN104769426B | 2017-11-28 | D.B.布雷曼; M.L.托卡斯 |
| 用于预测受试者对铁疗法的反应性的方法和与其有关的治疗方法。所述方法可用于与缺铁性贫血相关的疾患、病症或疾病。 | ||||||
| 3 | 用于预测接受他汀药物治疗的冠状动脉疾病患者的心血管后果的脂质组学生物标志 | CN201280054322.3 | 2012-11-07 | CN104024860A | 2014-09-03 | R·拉克松恩; K·埃克罗斯; R·霍尔姆; M·詹尼斯; R·卡塔恩; K·塔拉索夫 |
| 本发明特别提供一种方法及其应用，所述方法通过检测生物样品中的脂质浓度或脂质比率并将其与对照进行比较来预测诸如AMI或CVD死亡等严重的CVD并发症，本发明还鉴定出了特异性脂质标志，所述脂质标志在预测这些CVD并发症时比目前采用的临床标志具有更高的特异性和灵敏度。本发明还提供了抗所述脂质的抗体及其在预测、诊断、预防和/或治疗CVD并发症中的应用。本发明还涉及用于预测和/或诊断CVD并发症的包含脂质和/或其抗体的试剂盒。 | ||||||
| 4 | 用于预测接受他汀药物治疗的冠状动脉疾病患者的心血管后果的脂质组学生物标志 | CN201280054322.3 | 2012-11-07 | CN104024860B | 2017-06-06 | R·拉克松恩; K·埃克罗斯; R·霍尔姆; M·詹尼斯; R·卡塔恩; K·塔拉索夫 |
| 本发明特别提供一种方法及其应用，所述方法通过检测生物样品中的脂质浓度或脂质比率并将其与对照进行比较来预测诸如AMI或CVD死亡等严重的CVD并发症，本发明还鉴定出了特异性脂质标志，所述脂质标志在预测这些CVD并发症时比目前采用的临床标志具有更高的特异性和灵敏度。本发明还提供了抗所述脂质的抗体及其在预测、诊断、预防和/或治疗CVD并发症中的应用。本发明还涉及用于预测和/或诊断CVD并发症的包含脂质和/或其抗体的试剂盒。 | ||||||
| 5 | 肺结核疗效评价试剂盒及其应用 | CN201510218954.4 | 2015-04-30 | CN104808003A | 2015-07-29 | 李继承; 王冲 |
| 本发明公开了一种肺结核疗效评价试剂盒，包括五种酶标板、蛋白标准品组合物，生物素标记抗体组合物；其中所述酶标板分别包被有抗ALB抗体、抗APOA抗体、抗C3抗体、抗ARHGDIB抗体、抗FCN2抗体五种酶标板；所述蛋白标准品组合物包括ALB、APOA、ARHGDIB、C3和FCN2蛋白标准品；所述生物素标记抗体组合物包括所述生物素标记的抗ALB抗体、生物素标记的抗APOA抗体、生物素标记的抗ARHGDIB抗体、生物素标记的抗C3抗体和生物素标记的抗FCN2抗体。该肺结核疗效评价试剂盒可以高效、准确的评价肺结核病患者的治疗效果。 | ||||||
| 6 | 治疗缺铁性贫血的方法 | CN201380050782.3 | 2013-07-26 | CN104769426A | 2015-07-08 | D.B.布雷曼; M.L.托卡斯 |
| 用于预测受试者对铁疗法的反应性的方法和与其有关的治疗方法。所述方法可用于与缺铁性贫血相关的疾患、病症或疾病。 | ||||||
| 7 | CRP非免疫纳米金检测试纸条及其制备 | CN201310289752.X | 2013-07-11 | CN104280550A | 2015-01-14 | 游绍进; 陈琼; 张钲; 李为 |
| 本发明提供了用于检测CRP的非免疫纳米金试纸条的制备方法，包括：将标记有生物素的第一寡核苷酸标记到纳米金颗粒上并喷在结合垫上，将第二寡核苷酸喷在硝酸纤维膜上形成检测线并将亲和素喷在硝酸纤维膜上形成质控线，将样品垫、纳米金结合垫、硝酸纤维膜和吸水垫依次排列固定在支撑板上，由此制成。另外，本发明还提供了由该方法制成的试纸条及其应用等。 | ||||||
| 8 | 人胰高血糖素样肽-1、抗体及其试剂盒 | CN201410489841.3 | 2014-09-23 | CN104267194A | 2015-01-07 | 范列英; 刘颖冰 |
| 本发明公开了四种胰高血糖素样肽-1，公开了能够识别上述四种多肽的单克隆，公开了能识别上述四种多肽的多克隆抗体，本发明还公开了一种检测血清、或者血浆GLP-1总含量的ELISA试剂盒，包括有生物活性的GLP-1(7-37)、GLP-1(7-36)NH2肽、无生物活性的GLP-1(9-37)和GLP-1(9-36)NH2肽、四种肽链BSA融合蛋白、能够识别上述四种GLP-1的单克隆抗体、多克隆抗体和酶标记多克隆抗体。本发明是一种快速、稳定、可靠的诊断、治疗及疗效检测GLP-1缺乏相关性疾病的有效工具。 | ||||||
| 9 | 用于预测未接受他汀药物治疗的冠状动脉疾病患者的心血管后果的脂质组学生物标志 | CN201280054323.8 | 2012-11-07 | CN103917876A | 2014-07-09 | R·拉克松恩; K·埃克罗斯; R·霍尔姆; M·詹尼斯; R·卡塔恩; K·塔拉索夫 |
| 本发明特别提供一种方法及其应用，所述方法通过检测生物样品中的脂质浓度或脂质比率并将其与对照进行比较来预测诸如AMI或CVD死亡等严重的CVD并发症，本发明还鉴定出了特异性脂质标志，所述脂质标志在预测这些CVD并发症时比目前采用的临床标志具有更高的特异性和灵敏度。本发明还提供了抗所述脂质的抗体及其在预测、诊断、预防和/或治疗CVD并发症中的应用。本发明还涉及用于预测和/或诊断CVD并发症的包含脂质和/或其抗体的试剂盒。 | ||||||
| 10 | 过敏性疾病变应原胶体金诊断试纸条及其制备方法 | CN201310718509.5 | 2013-12-23 | CN103675271A | 2014-03-26 | 白彩明; 马晓晖; 汤承祁; 裴潇竹; 姜敏; 李雪妮; 王兆仿 |
| 本发明提供一种过敏性疾病变应原胶体金诊断试纸条，所述试纸条包括样品孔、胶体金垫、膜条、吸水垫和PVC板，其中膜条包被有吸入组过敏原Ⅰ、吸入组过敏原Ⅱ、食物组过敏原以及鼠抗羊IgG抗体，形成三条检测带和一条质控带。该试纸条包括的每一种变应原能代表80%患者群体的变应原分子，在检测膜条上，用包被标志性变应原分子代替变应原提取物，从技术上实现了快速诊断过敏性疾病的目的。用该试纸条检测耗时5～30分钟，特异性强、灵敏度高、简易快速，能现场检测，操作人员无需专业培训，按说明书即可完成操作，实现过敏性疾病的快速诊断。 | ||||||
| 11 | 体重増加予防のためのプレバイオティクス効力のバイオマーカーとしてのインドキシル硫酸 | JP2016504557 | 2014-03-13 | JP6367915B2 | 2018-08-01 | マルタン, フランソワ‐ピエール; コリノ, セバスティアーノ; モントリュー ロウラ, アイヴァン |
| 12 | Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen | US16245249 | 2019-01-10 | US20190214145A1 | 2019-07-11 | Itzhak Kurek; Robert McKee; Mike Siani-Rose |
| Disclosed are methods and systems for building a database of metabolite profiles correlated with disease states and treatment regiments, then defining an individual patient's metabolite profile, and then screening the patient's profile against the database to recommend potential effective treatment regimens. | ||||||
| 13 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment | US15210048 | 2016-07-14 | US09863965B2 | 2018-01-09 | Reijo Laaksonen; Kim Ekroos; Reini Hurme; Riikka Katainen |
| The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | ||||||
| 14 | HUMAN BETA-ADRENERGIC RECEPTOR KINASE POLYPEPTIDE AND METHODS | US15624487 | 2017-06-15 | US20170283783A1 | 2017-10-05 | Vicki S. Kaulback; Reena Khare; Thomas W. Richardson; Joseph P. Marquis; Anita Swarnakar; April J. A. Hafalia; Shanya D. Becha; Narinder K. Chawla-Walia; Mariah R. Baughn; Soo Yeun Lee; Uyen K. Tran; Henry Yue; Danniel B. Nguyen; Michael B. Thorton; Rajagopal Gururajan; Ameena R. Gandhi; Yan Lu; Monique G. Yao; Joana X. Li; Wen Luo; Ernestine A. Lee; Craig H. Ison; Amy D. Wilson; Pei Jin; Ian J. Forsythe |
| Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP. | ||||||
| 15 | VALIDATING BIOMARKER MEASUREMENT | US15160749 | 2016-05-20 | US20160350477A1 | 2016-12-01 | Leo Charles MCHUGH |
| A method for validating quantification of biomarkers, the biomarkers being quantified using a quantification technique of a selected type, and the method including determining a plurality of biomarker values, each biomarker value being indicative of a value measured or derived from a measured value, for at least one corresponding biomarker of the biological subject and being at least partially indicative of a concentration of the biomarker in a sample taken from the subject, determining at least one control value by determining a combination of biomarker values, comparing each control value to a respective control reference and determining if the biomarker values are valid using results of the comparison. | ||||||
| 16 | Isovalerylglycine as biomarker for the predispositon for weight gain and obesity | US14649072 | 2013-11-25 | US09500660B2 | 2016-11-22 | Francois-Pierre Martin; Claire L. Boulange; Ivan Montoliu Rora; Sebastiano Collino; Marc-Emmanuel Dumas; Elaine Holmes; Serge Andre Dominique Rezzi; Jeremy Nicholson; Sunil Kochhar |
| The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a method that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be isovalerylglycine. | ||||||
| 17 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment | US14723754 | 2015-05-28 | US09459265B2 | 2016-10-04 | Reijo Laaksonen; Kim Ekroos; Reini Hurme; Riikka Katainen |
| The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | ||||||
| 18 | ALPHA-KETO-ISOVALERATE AS A BIOMARKER OF PREBIOTIC EFFICACY FOR WEIGHT GAIN PREVENTION | US14774655 | 2014-03-13 | US20160033474A1 | 2016-02-04 | Francois-Pierre Martin; Sebastiano Collino; Ivan Montoliu Roura |
| The present invention relates generally to the field of nutrition and health, particular, the present invention relates to alpha-keto-isovalerate as a biomarker urine of the efficacy of prebiotics for the prevention of diet induced weight gain. | ||||||
| 19 | EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS | US14761690 | 2014-01-17 | US20150362493A1 | 2015-12-17 | Daniel J. Sexton; Ryan Faucette; Jon A. Kenniston; Gregory P. Conley; Andrew Nixon; Christopher TenHoor; Burt Adelman; Yung Chyung |
| The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen. | ||||||
| 20 | LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS UNDERGOING STATIN TREATMENT | US14723754 | 2015-05-28 | US20150260738A1 | 2015-09-17 | Reijo Laaksonen; Kim EKROOS; Reini Hurme; Riikka Katainen |
| The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | ||||||
QQ群二维码
意见反馈
意见反馈